title: Platelet aggregation pathway network-based approach for evaluating compounds efficacy.
abstract: Traditional Chinese medicines (TCMs) contain a large quantity of compounds with multiple biological activities. By using multitargets docking and network analysis in the context of pathway network of platelet aggregation, we proposed network efficiency and network flux model to screen molecules which can be used as drugs for antiplatelet aggregation. Compared with traditional single-target screening methods, network efficiency and network flux take into account the influences which compounds exert on the whole pathway network. The activities of antiplatelet aggregation of 19 active ingredients separated from TCM and 14 nonglycoside compounds predicated from network efficiency and network flux model show good agreement with experimental results (correlation coefficient = 0.73 and 0.90, resp.). This model can be used to evaluate the potential bioactive compounds and thus bridges the gap between computation and clinical indicator.
authors: Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory of Rare Earth Materials Chemistry and Applications, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China.
authors: Jiangyong
authors: J
authors: Gu
authors: Qian
authors: Q
authors: Li
authors: Lirong
authors: L
authors: Chen
authors: Youyong
authors: Y
authors: Li
authors: Tingjun
authors: T
authors: Hou
authors: Gu
authors: G
authors: Yuan
authors: Xiaojie
authors: X
authors: Xu
references: EMBO Rep. 2009 Aug;10 Suppl 1:S9-13
references: 19636307
references: Chem Cent J. 2008 Sep 08;2:18
references: 18778471
references: Nat Biotechnol. 2004 Oct;22(10):1253-9
references: 15470465
references: Clin Pharmacol Ther. 2007 Jan;81(1):126-8
references: 17186011
references: Nat Rev Drug Discov. 2009 Apr;8(4):286-95
references: 19337271
references: Nat Chem Biol. 2008 Nov;4(11):682-90
references: 18936753
references: Drug Discov Today Technol. 2006 Autumn;3(3):247-53
references: 24980525
references: Nucleic Acids Res. 2010 Jan;38(Database issue):D355-60
references: 19880382
references: Mol Biosyst. 2009 Dec;5(12):1536-48
references: 19763339
references: Proteins. 2006 Nov 15;65(3):549-54
references: 16988956
references: Phys Rev E Stat Nonlin Soft Matter Phys. 2005 May;71(5 Pt 1):051909
references: 16089573
references: Nat Rev Drug Discov. 2005 Jan;4(1):71-8
references: 15688074
references: Trends Pharmacol Sci. 2005 Apr;26(4):178-82
references: 15808341
references: Pharmacogenet Genomics. 2011 Aug;21(8):516-21
references: 20938371
references: FEBS Lett. 2008 Apr 9;582(8):1259-65
references: 18282477
references: Nat Rev Drug Discov. 2003 Oct;2(10):775-89
references: 14526381
references: Drugs. 2008;68(12):1647-64
references: 18681489
references: Thromb Res. 2008;123(1):35-49
references: 18571699
references: Clin Pharmacol Ther. 2010 Jul;88(1):120-5
references: 20520604
references: Nucleic Acids Res. 2005 Jan 1;33(Database issue):D428-32
references: 15608231
references: J Biol. 2008 Jul 31;7(6):20
references: 18710588
references: Bioinformatics. 2010 Feb 15;26(4):529-35
references: 20031970
references: Clin Pharmacol Ther. 2010 Jul;88(1):25-33
references: 20531468
references: PLoS One. 2011 Mar 22;6(3):e14774
references: 21445339
references: Thromb Res. 2012 Mar;129(3):245-9
references: 22119499
references: Nature. 2002 Nov 14;420(6912):206-10
references: 12432404
references: Phys Rev Lett. 2001 Nov 5;87(19):198701
references: 11690461